Jpmorgan Chase & CO Ice Cure Medical Ltd. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ICCM
# of Institutions
15Shares Held
294KCall Options Held
0Put Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il170KShares$98,3160.0% of portfolio
-
Ubs Group Ag59.9KShares$34,7380.0% of portfolio
-
Virtu Financial LLC New York, NY27.2KShares$15,7690.0% of portfolio
-
Geode Capital Management, LLC Boston, MA25.6KShares$14,8240.0% of portfolio
-
Two Sigma Investments, LP New York, NY18.5KShares$10,7440.0% of portfolio
About IceCure Medical Ltd.
- Ticker ICCM
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 36,835,600
- Market Cap $21.4M
- Description
- IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.